Education
About Us
Working with TipRanks
Follow Us
Cochlear Limited (CHEOF)
OTHER OTC:CHEOF
CHEOF Stock Chart & Stats
$191.36
$5.64(3.10%)
At close: 4:00 PM EST
$191.36
$5.64(3.10%)
Day’s Range― - ―
52-Week Range$148.62 - $209.45
Previous CloseN/A
Volume5.00
Average Volume (3M)33.00
Market Cap
$11.87B
Enterprise Value$19.66B
Total Cash (Recent Filing)$275.70M
Total Debt (Recent Filing)$235.70M
Price to Earnings (P/E)46.9
Beta0.25
Next Earnings
Feb 18, 2026EPS Estimate
2.07Last Dividend Ex-Date
Sep 19, 2025Dividend Yield1.53%
Share Statistics
EPS (TTM)1.83
Shares Outstanding65,398,460
10 Day Avg. Volume16
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio5.50
Price to Book (P/B)10.08
Price to Sales (P/S)8.39
P/FCF Ratio145.62
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue8.34
Enterprise Value/Gross Profit11.29
Enterprise Value/Ebitda32.23
Forecast
1Y Price Target
$199.61Price Target Upside4.31% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial OutlookCOH has guided to FY26 NPAT of A$435-460mn, with a stronger weighting to 2H26 based on the timing of the launch of the Nexa implant, implying 2H26 NPAT growth of +13-25%.
Market PositionWith the launch of the Nucleus Nexa, there is optimism that the company can sustain its market-leading position.
Product LaunchThe launch of a new implant – the Nucleus Nexa – offering an enhanced patient experience, is expected to attract both physicians and patients and see double-digit growth for implants.
Bears Say
Processor VolumesProcessors experienced a decline in volumes due to a mix of cost of living and other factors, making the outlook for services sales less optimistic.
Sales EstimatesMid-term sales estimates fall 5-6% on lower services sales growth, which resulted in a decrease in the price target from AUD350 to AUD320.
Services GrowthUncertainty around near-term services growth has led to a downgrade of COH shares from Buy to Neutral.
Cochlear News
CHEOF FAQ
What was Cochlear Limited’s price range in the past 12 months?
Cochlear Limited lowest stock price was $148.62 and its highest was $209.45 in the past 12 months.
What is Cochlear Limited’s market cap?
Cochlear Limited’s market cap is $11.87B.
When is Cochlear Limited’s upcoming earnings report date?
Cochlear Limited’s upcoming earnings report date is Feb 18, 2026 which is in 80 days.
How were Cochlear Limited’s earnings last quarter?
Cochlear Limited released its earnings results on Aug 14, 2025. The company reported $1.834 earnings per share for the quarter, missing the consensus estimate of $1.905 by -$0.072.
Is Cochlear Limited overvalued?
According to Wall Street analysts Cochlear Limited’s price is currently Undervalued.
Does Cochlear Limited pay dividends?
Cochlear Limited pays a Semiannually dividend of $1.422 which represents an annual dividend yield of 1.53%. See more information on Cochlear Limited dividends here
What is Cochlear Limited’s EPS estimate?
Cochlear Limited’s EPS estimate is 2.07.
How many shares outstanding does Cochlear Limited have?
Cochlear Limited has 65,398,460 shares outstanding.
What happened to Cochlear Limited’s price movement after its last earnings report?
Cochlear Limited reported an EPS of $1.834 in its last earnings report, missing expectations of $1.905. Following the earnings report the stock price went up 0.36%.
Which hedge fund is a major shareholder of Cochlear Limited?
Currently, no hedge funds are holding shares in CHEOF
Cochlear Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$199.61 (4.31% Upside)
$199.61 (4.31% Upside)
Insider Transactions
Sold Shares
Worth $760.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.14%
12-Months-Change
Fundamentals
Return on Equity
20.11%
Trailing 12-Months
Asset Growth
0.98%
Trailing 12-Months
Company Description
Cochlear Limited
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
CHEOF Company Deck
CHEOF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of achievements, such as the successful launch of the Nexa system and growth in specific product segments, countered by challenges like declining services revenue, slower overall sales growth, and margin pressures. The outlook includes cautious optimism with expectations of growth driven by new product launches, but also acknowledges ongoing uncertainties in key markets.View all CHEOF earnings summariesCHEOF Stock 12 Month Forecast
Average Price Target
$199.61
▲(4.31% Upside)
Technical Analysis
Polynovo
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Ownership Overview
0.10% Insiders
5.45% Mutual Funds
<0.01% Other Institutional Investors
85.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---